Cellomatics targets strategic growth with key hire  

Contract research organisation (CRO) Cellomatics Biosciences has appointed a new senior director to help it expand. The company has hired Anand Krishna as senior director to help oversee customer care and management, sales, operations, and marketing. Krishna has over 25 years of executive leadership and field sales management experience in companies ranging from VC-funded dotcom start-ups, to managing sales across portfolios in tier 1 technology systems and operations integrators. 

In particular, Krishna will focus on connecting with entrepreneurs across a diverse set of aspirational businesses to provide strategic support. 

Official comments 

Commenting on his appointment at Cellomatics, Krishna said: “I have admired and followed Cellomatics from its foundation and I am delighted to be joining such a fast-growing and dynamic CRO. I am looking forward to the opportunity to work and learn from an energetic team of research scientists who play an active role in supporting the discovery and developments of treatments for diseases such as cancer, COPD and Alzheimer’s. The company is on an exciting growth trajectory, and my priority is to bring best practices and processes to the company to support the continued rapid growth.” 

Cellomatics’ CEO and founder, Dr Shailendra Singh, added: “We are on an ambitious growth curve which is fueled by an increasing demand for our expertise in preclinical cell-based assay development in the oncology, respiratory, immunology, inflammation, and immuno-oncology therapeutic areas. As we grow, it is important to develop our infrastructure and bring in the expertise to support our commercial objectives. Anand’s wealth of experience in working with entrepreneurs will be an invaluable asset to Cellomatics, and I am delighted to welcome him to the team.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free